Venture Certified
| 연구개발유형 | 2023-08-23 ~ 2026-08-22 | 20230823020006 | 2023-08-23 |
Revenue CAGR +941.9%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 5.4B | 1.1B | 0.1B |
| Operating Profit | -29.2B | -29.8B | -30.8B |
| Net Profit | -32.6B | -32.4B | -31.6B |
| Total Assets | 16.1B | 7.7B | 10.5B |
| Total Liabilities | 106.0B | 112.3B | 82.4B |
| Total Equity | -89.9B | -104.6B | -71.9B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -29B
3 Consecutive Years of Net Loss
▲ 883.3%
▲ 3.5%
▲ 98.3%
▼ 6.2%
▼ 3.2%
| Name | Position | Role |
|---|---|---|
| 박한오 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "대전광역시 대덕구",
"ceo_name": "박한오",
"certificate": [
{
"cert_number": "20230823020006",
"changes": "",
"disclosure_date": "2023-08-23",
"first_cert_date": "2023-08-23",
"no": "1",
"type": "연구개발유형",
"valid_period": "2023-08-23 ~ 2026-08-22"
}
],
"company_name": "(주)써나젠테라퓨틱스",
"corp_no": "160111-*******",
"financials": {
"2022": {
"capital_stock": 1500000000,
"cost_of_sales": 0,
"current_assets": 703536000,
"current_liabilities": 2254867000,
"gross_profit": 5000000,
"net_income": -3156512000,
"net_income_bs": -3156512000,
"non_current_assets": 346560000,
"non_current_liabilities": 5980297000,
"non_operating_expenses": 157709000,
"non_operating_income": 79038000,
"operating_profit": -3077841000,
"revenue": 5000000,
"sga_expenses": 3082841000,
"total_assets": 1050096000,
"total_equity": -7185068000,
"total_liabilities": 8235164000
},
"2023": {
"capital_stock": 1500000000,
"cost_of_sales": 0,
"current_assets": 66730000,
"current_liabilities": 8133557000,
"gross_profit": 105400000,
"net_income": -3239661000,
"net_income_bs": -3239661000,
"non_current_assets": 702672000,
"non_current_liabilities": 3099822000,
"non_operating_expenses": 274463000,
"non_operating_income": 12570000,
"operating_profit": -2977768000,
"revenue": 105400000,
"sga_expenses": 3083168000,
"total_assets": 769402000,
"total_equity": -10463977000,
"total_liabilities": 11233379000
},
"2024": {
"capital_stock": 6300000000,
"cost_of_sales": 0,
"current_assets": 815354000,
"current_liabilities": 10145305000,
"gross_profit": 542809000,
"net_income": -3260143000,
"net_income_bs": -3260143000,
"non_current_assets": 794948000,
"non_current_liabilities": 456719000,
"non_operating_expenses": 341412000,
"non_operating_income": 3481000,
"operating_profit": -2922212000,
"revenue": 542809000,
"sga_expenses": 3465021000,
"total_assets": 1610302000,
"total_equity": -8991722000,
"total_liabilities": 10602024000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "신약연구개발",
"phone": "042-939-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |